"The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
Calcium Chloride Injection 10%
This solution is suitable only for intravenous use. Calcium chloride (calcium chloride) solution injection into muscle or into subcutaneous or perivascular tissue may cause severe necrosis and sloughing. Intravenous injections of this drug must be made with great care to avoid leakage into the perivascular tissue.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
To avoid undesirable reactions that may follow intravenous administration of calcium chloride (calcium chloride) , the rate of injection should not exceed 0.5 mLto 1 mLper minute.
Because of the danger involved in the simultaneous use of calcium salts and drugs of the digitalis group, a digitalized patient should not receive an intravenous injection of a calcium compound unless the indications are clearly defined.
Use In Pregnancy
Safety for use in pregnancy has not been established. Use of calcium chloride (calcium chloride) in women of childbearing potential requires that anticipated benefits be weighed against possible hazards.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/30/2008
Additional Calcium Chloride Injection 10% Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.